What Biogen Wants in Return for Financial Assistance of Its $750,000 a Year Drug

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x470-biogen.jpg" NAME"What Biogen Wants in Return for Financial Assistance of Its $750,000 a Year Drug" ALT"What Biogen Wants in Return for Financial Assistance of Its $750,000 a Year Drug"June…

Continue ReadingWhat Biogen Wants in Return for Financial Assistance of Its $750,000 a Year Drug

Bay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen's Neulasta

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-fda.jpg" NAME"Bay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen's Neulasta" ALT"Bay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen's Neulasta"June 12, 2017By…

Continue ReadingBay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen's Neulasta

Sanofi's Rumored Buyout Target Flexion Shows Off Mid-Stage Osteoarthritis Data

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks5.jpg" NAME"Sanofi's Rumored Buyout Target Flexion Shows Off Mid-Stage Osteoarthritis Data" ALT"Sanofi's Rumored Buyout Target Flexion Shows Off Mid-Stage Osteoarthritis Data"June 12, 2017By Mark Terry, BioSpace.com... Source: BioSpace

Continue ReadingSanofi's Rumored Buyout Target Flexion Shows Off Mid-Stage Osteoarthritis Data

TGA Plans to Allow Automatic, Instant Approvals of Lowest-Risk Product Variations

The Australian Therapeutic Goods Administration issued an industry guidance proposing to quickly approve certain types of low-risk variations to registered medicines without requiring evaluation, allowing sponsors to implement the changes…

Continue ReadingTGA Plans to Allow Automatic, Instant Approvals of Lowest-Risk Product Variations